Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) New England Journal of Medicine In 3,297 patients with T2D, semaglutide reduced major adverse cardiovascular events by 26% versus placebo over 2.1 years (HR 0.74), driven by 39% stroke reduction and 26% nonfatal MI reduction
How Long Do the Results Last, and Should It Be Ongoing Clinical trials indicate that Semaglutide is intended for sustained use when effective
Researchers think that the satiety effects of GLP-1s may be related to their actions on the brains dopamine reward system
UT Southwestern recommends that patients with obesity work with an obesity specialist along with their Ob/Gyn before, during, and after pregnancy to reduce potential risks and increase the chances for a healthy pregnancy
People who have been prescribed a weight-loss injection could be at a higher risk of developing an eye condition which can lead to blindness, a study has found